Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lam, Raymond W.; Milev, Roumen; Rotzinger, Susan; Andreazza, Ana C.; Blier, Pierre; Brenner, Colleen; Daskalakis, Zafiris J.; Dharsee, Moyez; Downar, Jonathan; Evans, Kenneth R.; Farzan, Faranak; Foster, Jane A.; Frey, Benicio N.; Geraci, Joseph; Giacobbe, Peter; Feilotter, Harriet E.; Hall, Geoffrey B.; Harkness, Kate L.; Hassel, Stefanie; Ismail, Zahinoor; Leri, Francesco; Liotti, Mario; MacQueen, Glenda M.; McAndrews, Mary Pat; Minuzzi, Luciano; Müller, Daniel J.; Parikh, Sagar V.; Placenza, Franca M.; Quilty, Lena C.; Ravindran, Arun V. ... view all 37 authors View less authors (2016)
Publisher: Biomed Central
Journal: BMC Psychiatry
Languages: English
Types: Article
Subjects: Study Protocol, Psychiatry and Mental health
Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. Methods: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. Discussion: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. Trial registration: ClinicalTrials.gov identifier NCT01655706. Registered July 27, 2012.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, Whiteford HA. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One. 2013;8(7):e69637.
    • 2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800.
    • 3. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334-41.
    • 4. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS. Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health. Grand challenges in global mental health. Nature. 2011;475:27-30.
    • 5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
    • 6. Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976-89.
    • 7. Stuss DT. The Ontario Brain Institute: completing the circle. Can J Neurol Sci. 2014;41(6):683-93.
    • 8. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22-33. quiz 34-57.
    • 9. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(16):10-7.
    • 10. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy J Affect Disord. 2009;117(1):S26-43.
    • 11. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
    • 12. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-53.
    • 13. Thase ME, Trivedi MH, Nelson JC, Fava M, Swanink R, Tran QV, Pikalov A, Yang H, Carlson BX, Marcus RN, Berman RM. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry. 2008;10(6):440-7.
    • 14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
    • 15. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52-8.
    • 16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
    • 17. Kalali A, Vaccarino A, Evans K, Kennedy S, Kobak K, Sills T, Sheehan D, Williams J, Greist J, Schatzberg A. P.2.a.010 The depression inventory development workgroup: Results from the second validation study. Euro Neuropsychopharm. 2008;18(4):S298.
    • 18. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16- Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-83.
    • 19. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.
    • 20. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
    • 21. Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, Skeppar P, Vieta E, Scott J. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88(2):217-33.
    • 22. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93-105.
    • 23. Lam RW, Michalak EE, Yatham LN. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. BMC Psychiatry. 2009;9:78.
    • 24. The WHOQOL Group. The development of the World Health Organization quality of life assessment instrument (the WHOQOL). In: Orley J, Kuyken W, editors. Quality of Life Assessment: International Perspectives. Heidelberg: Springer Verlag; 1994. p. 41-57.
    • 25. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2):321-6.
    • 26. Carver CS, White TL. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS Scales. J Pers Soc Psychol. 1994;67(2):319-33.
    • 27. Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Michael Bagby R, Kennedy SH. Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. Psychiatry Res. 2015;229(1-2):109-19.
    • 28. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99-103.
    • 29. Costa PT, McCrae RR. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI) Professional Manual. Odessa: Psychological Assessment Resources, Inc.; 1992.
    • 30. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR & Loeser JD (eds.), Issues in Pain Measurement. Advances in Pain Research and Therapy, Volume.12. New York: Raven Press; 1989; 391-403.
    • 31. Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
    • 32. Giglio LM, Magalhães PV, Andreazza AC, Walz JC, Jakobson L, Rucci P, Rosa AR, Hidalgo MP, Vieta E, Kapczinski F. Development and use of a biological rhythm interview. J Affect Disord. 2009;118(1-3):161-5.
    • 33. Magnusson A. Validation of the Seasonal Pattern Assessment Questionnaire (SPAQ). J Affect Disord. 1996;40(3):121-9.
    • 34. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-95.
    • 35. Fraley RC, Waller NG, Brennan KA. An item response theory analysis of selfreport measures of adult attachment. J Pers Soc Psychol. 2000;78(2):350-65.
    • 36. Brugha TS, Cragg D. The List of Threatening Experiences: the reliability and validity of a brief life events questionnaire. Acta Psychiatr Scand. 1990;82(1):77-81.
    • 37. Bifulco A, Brown GW, Harris TO. Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry. 1994; 35(8):1419-35.
    • 38. Bifulco A, Brown G, Edwards A, Harris T, Neilson E, Richards C, Robinson R. Life Events and Difficulties Schedule (LEDS-2): Vol. 1. Life events manual. London: Royal Holloway and Bedford New College, University of London; 1989.
    • 39. Iverson GL, Brooks BL, Young AH. Identifying neurocognitive impairment in depression using computerized testing. Appl Neuropsychol. 2009;16(4):254-61.
    • 40. Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol. 2006;21(7):623-43.
    • 41. Nelson HE. National Adult Reading Test (NART): Test manual (Part1). Windsor: NFER-NELSON Publishing Company Ltd.; 1982.
    • 42. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002; 47(2):174-80.
    • 43. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressantinduced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61(4):276-81.
    • 44. Glover GH, Mueller BA, Turner JA, van Erp TG, Liu TT, Greve DN, Voyvodic JT, Rasmussen J, Brown GG, Keator DB, Calhoun VD, Lee HJ, Ford JM, Mathalon DH, Diaz M, O'Leary DS, Gadde S, Preda A, Lim KO, Wible CG, Stern HS, Belger A, McCarthy G, Ozyurt B, Potkin SG. Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. J Magn Reson Imaging. 2012;36(1):39-54.
    • 45. Kurmis AP, Barber C, Slavotinek JP, Fazzalari NL. A MnCl2-based MR signal intensity linear response phantom. Radiol Technol. 2007;79(2):119-25.
    • 46. Friedman L, Glover GH. Report on a multicenter fMRI quality assurance protocol. J Magn Reson Imaging. 2006;23(6):827-39.
    • 47. Fonov VS, Janke A, Caramanos Z, Arnold DL, Narayanan S, Pike GB, Collins DL. Improved precision in the measurement of longitudinal global and regional volumetric changes via a novel MRI gradient distortion characterization and correction technique. In: Laio H, editor. Medical Imaging and Augmented Reality. Lecture Notes in Computer Science, vol. 6326. Berlin Heidelberg: Springer; 2010. p. 324-33.
    • 48. Alzheimer's Disease Neuroimaging Insitiative MRI Technical Procedures Manual. [Internet]. 2013 [cited 2016 February 5]. Available from: http:// www.adni-info.org/Scientists/doc/ADNI2MRITrainingManualVersion5_ Oct2014_CLEAN.pdf.
    • 49. Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage. 2007;37(4):1083-90. discussion 1097-9.
    • 50. Egner T, Etkin A, Gale S, Hirsch J. Dissociable neural systems resolve conflict from emotional versus nonemotional distracters. Cereb Cortex. 2008;18(6):1475-84.
    • 51. Etkin A, Egner T, Peraza DM, Kandel ER, Hirsch J. Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala. Neuron. 2006;51(6):871-82.
    • 52. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. The neural basis of moodcongruent processing biases in depression. Arch Gen Psychiatry. 2002;59(7): 97-604.
    • 53. Hall GB, Milne AM, MacQueen GM. An fMRI study of reward circuitry in patients with minimal or extensive history of major depression. Eur Arch Psychiatry Clin Neurosci. 2014;264(3):187-98.
    • 54. Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M, Claes S. Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry. 2013;73(7):639-45.
    • 55. Albert J, López-Martín S, Carretié L. Emotional context modulates response inhibition: neural and behavioral data. Neuroimage. 2010;49(1):914-21.
    • 56. Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics. J Neurosci Methods. 2004;134:9-21.
    • 57. Trevino V, Falciani F, Barrera-Saldaña HA. DNA microarrays: a powerful genomic tool for biomedical and clinical research. Mol Med. 2007; 13(9-10):527-41.
    • 58. Einat P. Methodologies for high-throughput expression profiling of microRNAs. Methods Mol Biol. 2006;342:139-57.
    • 59. Chiu CL, Randall S, Molloy MP. Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis. Bioanalysis. 2009;1(4):847-55.
    • 60. High Performance Computing Virtual Lab [Internet]. Kingston, ON, Canada: High Performance Computing Virtual Lab; 2016 [accessed 2016 Jan 30]. Available from:https://www.hpcvl.org/security/security-policy
    • 61. Gee T, Kenny S, Price CJ, Seghier ML, Small SL, Leff AP, Pacurar A, Strother SC. Data warehousing methods and processing infrastructure for brain recovery research. Archives Italiennes de Biologie. 2010; 148(3):207-17.
    • 62. National Electrical Manufacturers Association. NEMA PS3 / ISO 12052, Digital Imaging and Communications in Medicine (DICOM) Standard. Virginia; 2016.
    • 63. Vallon-Christersson J, Nordborg N, Svensson M, Häkkinen J. BASE - 2nd generation software for microarray data management and analysis. BMC Bioinformatics. 2009;10:330.
    • 64. Nelson EK, Piehler B, Eckels J, Rauch A, Bellew M, Hussey P, Ramsay S, Nathe C, Lum K, Krouse K, Stearns D, Connolly B, Skillman T, Igra M. LabKey Server: an open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics. 2011;12:71.
    • 65. Harris PA, Taylor T, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
    • 66. Mark J. NIfTI-1 Data Format: Neuroimaging Informatics Technology Initiative [Internet]. 2007 [cited 2016 February 5]. Available from: http://nifti.nimh.nih. gov/nifti-1.
    • 67. Statistics Canada; Ottawa, ON; Canada. Ethnic Origin Reference Guide, 2006 Census. Catalogue no. 97-562-GWE2006025. http://www12.statcan.gc.ca/ census-recensement/2006/ref/rp-guides/ethnic-ethnique-eng.cfm. Last modified: 4 May 2011.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article